Management of pemphigus
Authors:
Open Access
- 6 May 2014
- journal article
- review article
- Published by H1 Connect in F1000Prime Reports
- Vol. 6 (32) , 32
Abstract
Pemphigus is an autoimmune blistering disease characterized by cutaneous and mucosal blisters and erosions. Though systemic corticosteroids have been the mainstay of treatment for pemphigus over the years, more recently research has focused on steroid-sparing agents. This review looks at the commonly used steroid-sparing agents in pemphigus and the evidence from randomized controlled trials (RCTs) supporting their use.Keywords
This publication has 27 references indexed in Scilit:
- Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgarisJournal of the European Academy of Dermatology and Venereology, 2012
- Interventions for pemphigus vulgaris and pemphigus foliaceusCochrane Database of Systematic Reviews, 2009
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- Treatment of PemphigusArchives of Dermatology, 2008
- Multicenter Randomized, Double-blind, Placebo-Controlled, Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus VulgarisArchives of Dermatology, 2008
- Randomized controlled open-label trial of four treatment regimens for pemphigus vulgarisJournal of the American Academy of Dermatology, 2007
- The adjuvant therapy of pemphigus. An update.1996
- Pemphigus in Mali: a study of 30 cases.1996
- Endemic Pemphigus Foliaceus: Fogo SelvagemDermatologic Clinics, 1993
- Pemphigus Therapy with Oral Prednisolone Regimens A 5‐Year StudyInternational Journal of Dermatology, 1990